Company profile: Biohaven Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of clinical-stage biopharmaceutical therapies for neurological diseases, including rare disorders. Focuses on CGRP receptor antagonists, glutamate modulators and a myeloperoxidase inhibitor. Portfolio includes Nurtec ODT and Zavzpret for migraine, and pipeline candidates troriluzole, BHV-7000, taldefgrobep and BHV-2100 for OCD, SCA, epilepsy, bipolar disorder, SMA, obesity and neuropathic pain.
Products and services
- Nurtec ODT (rimegepant): An orally disintegrating CGRP receptor antagonist tablet engineered for both acute and preventive migraine treatment, supporting dual-use via targeted receptor blockade
- Troriluzole: An investigational prodrug of riluzole developed for neurological conditions, including OCD and spinocerebellar ataxia, targeting glutamate modulation via prodrug-based pharmacology
- Zavzpret (zavegepant): An intranasal CGRP antagonist formulated to relieve migraine symptoms quickly, offering fast-acting nasal delivery and receptor inhibition for ultra-rapid symptom control
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biohaven Pharmaceuticals
Autonomix
HQ: United States
Website
- Description: Provider of catheter-based sensing and proprietary ablation technologies that detect, differentiate, and target peripheral neural signals to treat pain or disease, offering an alternative to systemic drugs or blind approaches. Includes a catheter-deployed microchip with basket design converting analog to digital and first-in-class electrophysiology; initial focus on pancreatic cancer pain and minimally invasive renal denervation; supported by 15 patent families and 100+ patents.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Autonomix company profile →
Muna Therapeutics
HQ: Denmark
Website
- Description: Provider of biopharmaceutical therapies and discovery platforms to slow or stop neurodegenerative diseases including Alzheimer’s, Parkinson’s, Frontotemporal Dementia, and Multiple Sclerosis. Programs include TREM2 agonism for early-stage Alzheimer’s, Kv1.3 blockade for Parkinson’s and MS, and MiND-MAP, an all-in-human target discovery and validation platform using single cell spatial multi-omics in patient samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Muna Therapeutics company profile →
Transverse Medical
HQ: United States
Website
- Description: Provider of medical equipment, offering the POINT-GUARD™ Cerebral Embolic Protection Device to minimize stroke risk by filtering cerebral embolic debris during cardiovascular procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transverse Medical company profile →
Statera Spine
HQ: United States
Website
- Description: Provider of software-enabled spine imaging analytics solutions for chronic and acute spine issues, offering diagnostic and decision-making tools including Profile-ESP for standardized spinal motion and alignment data reports, and VMA, a fluoroscopy imaging system assessing spinal instability and sagittal alignment with measurements for surgical decisions and insurance disputes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Statera Spine company profile →
Atanse
HQ: United States
Website
- Description: Provider of precision neurosurgical instruments, offering a brain therapy delivery device that enables biotechnology companies to deliver therapies with greater precision and reduced trauma. The device adapts a traditional delivery cannula by incorporating a microcannula that extends and retracts at an angle from the tip, supporting neurosurgeons in targeted delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atanse company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biohaven Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biohaven Pharmaceuticals
2.2 - Growth funds investing in similar companies to Biohaven Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biohaven Pharmaceuticals
4.2 - Public trading comparable groups for Biohaven Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →